Abivax remains independent amid biotech M&A surge; strategic rationale unclear

Despite a record pace of biotech acquisitions, French drugmaker Abivax has not been acquired, prompting speculation about potential obstacles or strategic mismatches. The article suggests possible explanations but provides no confirmed details. The situation matters as it may signal valuation gaps or regulatory hurdles affecting M&A activity in the sector.